Compare DexCom, Inc. (DXCM) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Norwegian Cruise Line Holdings Ltd trades at $19.6 (market cap $9.06B). The key difference: DexCom, Inc. is far larger — about 3.1× Norwegian Cruise Line Holdings Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | NCLH | |
|---|---|---|
Market Cap | $28.06B | $9.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $26.94 |
52-Week Low | $54.84 | $14.79 |
Enterprise Value | $27.03B | $24.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Norwegian Cruise Line Holdings (NCLH) trades at $19.46, down 0.87% on the day, with technical indicators showing a neutral to bearish short-term bias. The company has demonstrated consistent earnings beats in recent quarters, with Q1 2026 EPS of $0.23 exceeding expectations of $0.15. Revenue growth has been steady, reaching $9.83 billion in 2025, while profitability metrics show a net income margin of 5.66% and strong ROE of 29.53%. Recent news highlights include positive coverage of Caribbean sailings and a new chief marketing officer appointment.
NCLH presents a mixed investment case with analyst consensus leaning bullish (55.55% buy ratings) and a $21.71 price target offering 11.6% upside. However, elevated debt levels ($11.78 billion long-term debt) and macroeconomic sensitivity pose significant risks. The stock's current valuation at 15.91x P/E appears reasonable relative to historical levels, but investors should weigh the company's operational recovery against ongoing balance sheet concerns and industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
